Drug intelligence / Profile preview

ALZT-OP2

Development stage: Unknown
Lead developer: AZTherapies
Modality: Small Molecules

Overview

ALZT-OP2 is an experimental disease-modifying drug candidate developed by AZTherapies for the treatment of Alzheimer's disease. It was designed as part of the company's therapeutic platform alongside its lead candidate, ALZT-OP1 (a combination of cromolyn and ibuprofen). While ALZT-OP1 was developed to inhibit amyloid-beta aggregation and neuroinflammation, ALZT-OP2 was described in early company communications as a complementary disease-modifying treatment. However, specific details regarding its chemical composition, biological targets, and mechanism of action have not been publicly disclosed. Following the failure of the Phase 3 COGNITE trial for ALZT-OP1 in 2021, the development status of ALZT-OP2 remains unclear, with no recent clinical updates provided by the developer.

Beyond the preview

Go deeper on ALZT-OP2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALZT-OP2.

Explore the full profile